May 07, 2024
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Apr 30, 2024
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Apr 10, 2024
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Apr 04, 2024
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Mar 05, 2024
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb 27, 2024
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Feb 22, 2024
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
Jan 08, 2024
Rigel Pharmaceuticals Provides Business Update
Jan 04, 2024
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
Jan 03, 2024
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 29, 2021
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
Jan 11, 2021
Rigel Pharmaceuticals Provides Business Update
Jan 07, 2021
Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 04, 2020
Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
Nov 23, 2020
Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Nov 17, 2020
Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
Nov 10, 2020
Rigel to Present at the Jefferies Virtual London Healthcare Conference
Nov 05, 2020
Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update
Oct 29, 2020
Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update
Oct 09, 2020
Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova